Source https://www.fightaging.org/archives/2025/09/later-investors-eliminating-the-ownership-of-early-investors-is-an-ugly-reality-in-longevity-biotech/
The market for investment in biotechnology and pharmaceutical startup companies is tough at the best of times. Executive teams have to content with the broad valley of death that lies between enthusiasm for a company with early preclinical results in mice and enthusiasm for a company with initial human clinical data. Satisfying regulators, setting up Good Manufacturing Practice (GMP) manufacture of a drug, and producing that clinical data is exceptionally expensive, and the reality is that relatively few investors fund companies in the late preclinical stage, even when the market is good. As soon as the market sours, investors pull away from preclinical companies near entirely.
The l…
Source https://www.fightaging.org/archives/2025/09/later-investors-eliminating-the-ownership-of-early-investors-is-an-ugly-reality-in-longevity-biotech/
The market for investment in biotechnology and pharmaceutical startup companies is tough at the best of times. Executive teams have to content with the broad valley of death that lies between enthusiasm for a company with early preclinical results in mice and enthusiasm for a company with initial human clinical data. Satisfying regulators, setting up Good Manufacturing Practice (GMP) manufacture of a drug, and producing that clinical data is exceptionally expensive, and the reality is that relatively few investors fund companies in the late preclinical stage, even when the market is good. As soon as the market sours, investors pull away from preclinical companies near entirely.
The l…
What Do You Think?
comments